ClinicalTrials.gg
RecruitingNCT07844434Updated Oct 30, 2026

AI-Based Cardiac Analysis Using 12-Lead and 1-Lead ECG

An observational study in Heart Failure, Atrial Fibrillation (AF) and Electrocardiogram, sponsored by Inha University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Inha University Hospital · Observational

Updated Oct 30, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 148 studies in Heart Failure with a site in Korea, Republic of — 49 open to participants now, 54 under way, 12 of them phase 3. Heart Failure · Korea, Republic of.

Planned enrollment
29th of 39
300 · median 815
Started
2026
with 17 others
Observational
39 of 148
16 open now
Primary completion
2027-08
later than 18 of 53 live
Registered
145th of 148
by date

Among the 148 studies in Heart Failure with a site in Korea, Republic of, this one is the 29th largest by planned enrollment of the 39 observational ones that give a count, is one of 18 that started in 2026, is one of 39 observational ones, reaches primary completion later than 18 of the 53 other live ones, and was the 145th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

49 of the 148 studies in Heart Failure with a site in Korea, Republic of are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Heart Failure with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This pilot study is designed to evaluate the clinical performance and utility of the SmartECG-EF software in patients undergoing evaluations at Inha University Hospital. The primary objective is to assess how effectively the device assists clinicians in evaluating cardiac function and related clinical parameters. The study will prospectively enroll eligible participants to gather real-world clinical data, contributing to enhanced diagnostic accuracy and patient management.

Read the detailed description

This is a prospective, single-center pilot study conducted at Inha University Hospital to evaluate the clinical performance and feasibility of the SmartECG-EF software. Eligible participants will undergo standard clinical evaluations alongside the investigational device assessment. The study aims to investigate the diagnostic utility and operational workflow of integrating the software into routine clinical practice. Data regarding clinical parameters, primary and secondary outcome measures, and any device-related adverse events will be systematically collected and analyzed to assess safety and efficacy.

03

Conditions studied

  • Heart Failure
  • Atrial Fibrillation (AF)
  • Electrocardiogram

Keywords

  • Artificial Intelligence
  • Electrocardiogram
  • Heart Failure
  • Left Ventricular Dysfunction
  • Atrial Fibrillation
  • Pilot Study
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients visiting Inha University Hospital who undergo standard 12-lead and additional 1-lead ECG evaluations for cardiac assessment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written provided voluntarily by the subject
  • Age ≥ 19 years
  • Patients who undergo standard 12-lead measurement during the study period
  • Subjects with sinus rhythm on ECG at the time of examination
  • Subjects available for additional 1-lead ECG measurement during the same visit

Exclusion criteria

Exclusion Criteria:

  • Subjects deemed inappropriate or unlikely to comply with the study requirements by the investigator
  • Patients with atrial fibrillation or atrial flutter on at the time of examination
  • Patients with pacing rhythm due to a pacemaker
  • Subjects with severe tremor, uncooperativity, or skin conditions that make 1-lead ECG measurement difficult
  • Subjects whose additional study measurements would delay standard medical care due to a critical medical condition
  • Withdrawal of consent or refusal to agree to personal information usage
  • ECG with sub-standard quality (unanalyzable noise, lead disconnection, etc.; note: unanalyzable rate evaluation can be recorded separately)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • SmartECG-EF Evaluation Group

    Patients undergoing prospective evaluation using the SmartECG-EF software for cardiac function assessment and ECG-based parameter analysis at Inha University Hospital.

    Device: SmartECG-EF

Interventions

  • DeviceSmartECG-EF

    The SmartECG-EF software is used to analyze 12-lead and 1-lead electrocardiogram (ECG) data to evaluate cardiac function, including left ventricular systolic dysfunction (LVSD), heart failure indicators, and related arrhythmic parameters.

06

What researchers measure

Primary outcomes

  1. Correlation and Agreement between 12-Lead and 1-Lead AI Scores

    To evaluate the correlation (using Pearson or Spearman correlation coefficients), agreement (ICC using absolute agreement, two-way random model), and Bland-Altman analysis (mean difference and 95% limits of agreement) between 12-lead and 1-lead based AI scores.

    Time frame: Day 1

Secondary outcomes

  1. Area Under the ROC Curve (AUC-ROC) of AI scores

    To assess the AUC-ROC of 1-lead and 12-lead based AI results against disease-specific reference standards, including heart failure, left ventricular systolic dysfunction (LVSD), and arrhythmic parameters.

    Time frame: Baseline

  2. Sensitivity and Specificity of AI scores

    To assess sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 1-lead and 12-lead based AI results against disease-specific reference standards, including heart failure, left ventricular systolic dysfunction (LVSD), and arrhythmic parameters.

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — A specific plan for sharing individual participant data has not yet been finalized as this is a pilot study. Data sharing will be evaluated upon reasonable request and in accordance with institutional guidelines and IRB approvals.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 796 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's planned 9 months is below that.

Counting every sponsor, half of 978 studies reached it within 41 months; a quarter within 22 and three quarters within 89.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Sep 28, 2026
StartEst.
Nov 10, 2026was Aug 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
Inha University Hospital is now Recruiting
Oct 30, 2026
Start date
Aug 30, 2026→Nov 10, 2026
Oct 30, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    Inha University Hospital is now Recruiting
    Start date Aug 30, 2026→Nov 10, 2026
    + 1 other change: verification date
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844434
Lead sponsor
Inha University Hospital
Responsible party
Yong-Soo Baek (Professor, Inha University Hospital) — Principal investigator
First posted
Sep 28, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Yongsoo Baek, M.D., Ph.D.
Contact
existsoo@inha.ac.kr
+82-32-890-2200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion